BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo

BioMarin Pharmaceutical Inc. alleged Zydus Lifesciences Ltd.’s proposed copy of Voxzogo infringes a patent for the drug, which is used to treat children with a genetic condition causing dwarfism.

Zydus’ generic 0.4-, 0.56-, and 1.2-milligram injections of vosoritide, Voxzogo’s active ingredient, infringe US Patent No. 12,233,106, according to a complaint filed Monday in the US District Court for the District of New Jersey.

Voxzogo had sales of $735.1 million in 2024, 25.76% of BioMarin’s overall revenue, according to data compiled by Bloomberg.

The drug, administered as a once-daily injection, was the first approved in the US to treat achondroplasia, ...